Top Page
Alphamab Oncology
(9966)
Alphamab Oncology (9966) vs. iShares MSCI Hong Kong ETF (EWH)
Alphamab Oncology Business Overview & Revenue Model
Alphamab Oncology Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 785.96M | 640.08M | 218.77M | 166.84M | 146.02M | 0.00 |
| Gross Profit | 725.19M | 579.77M | 163.54M | 122.64M | 142.99M | 0.00 |
| EBITDA | 243.26M | 156.79M | -129.30M | -391.83M | -358.13M | -390.47M |
| Net Income | 232.81M | 166.34M | -210.59M | -325.72M | -412.42M | -427.77M |
Balance Sheet | ||||||
| Total Assets | 2.36B | 2.24B | 2.14B | 2.12B | 2.71B | 2.64B |
| Cash, Cash Equivalents and Short-Term Investments | 1.64B | 1.57B | 1.41B | 1.35B | 1.99B | 2.06B |
| Total Debt | 273.48M | 185.96M | 257.08M | 345.39M | 637.27M | 222.81M |
| Total Liabilities | 503.95M | 409.87M | 465.00M | 559.86M | 834.80M | 366.44M |
| Stockholders Equity | 1.85B | 1.83B | 1.67B | 1.56B | 1.87B | 2.27B |
Cash Flow | ||||||
| Free Cash Flow | 217.62M | 190.56M | -239.02M | -429.96M | -478.72M | -438.00M |
| Operating Cash Flow | 256.48M | 212.34M | -202.84M | -300.31M | -320.60M | -347.18M |
| Investing Cash Flow | -496.65M | -92.93M | -18.11M | 850.76M | 574.26M | -1.52B |
| Financing Cash Flow | -75.05M | -98.96M | 218.07M | -310.90M | 363.90M | 186.58M |
Alphamab Oncology Technical Analysis
Alphamab Oncology Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | HK$9.79B | 51.45 | 6.73% | ― | 23.37% | ― | |
54 Neutral | HK$12.49B | -44.18 | -12.74% | ― | -76.58% | -4.90% | |
53 Neutral | HK$10.65B | 41.67 | 13.34% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$12.36B | 18.94 | 35.80% | ― | 59.70% | 239.97% | |
45 Neutral | HK$2.35B | -11.90 | -55.33% | ― | -100.00% | 30.68% | |
40 Underperform | HK$9.91B | -47.34 | -21.42% | ― | 240.05% | -140.09% |
Alphamab Oncology Corporate Events
Alphamab Oncology announced that China’s Center for Drug Evaluation has officially accepted its Investigational New Drug application for a phase II clinical trial of JSKN033, a high-concentration subcutaneous co-formulation of a HER2 bispecific ADC and a PD-L1 immune checkpoint inhibitor, in combination with platinum-based chemotherapy with or without bevacizumab as a first-line treatment for advanced cervical cancer. The open-label, multicenter study will assess the safety, efficacy and pharmacokinetic/pharmacodynamic profile of JSKN033 plus cisplatin or carboplatin, and potentially bevacizumab, marking a significant step in advancing Alphamab’s novel combination biologic and reinforcing its strategy to build a differentiated oncology portfolio that could enhance its competitive position in the global cancer therapeutics market.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its breakthrough HER2-targeting ADC, JSKN003, has been granted Breakthrough Therapy Designation (BTD) by the FDA for advanced platinum-resistant ovarian and related cancers, signaling the therapy’s clinical potential amid significant unmet treatment needs. This milestone reinforces Alphamab’s position in oncology innovation, as it accelerates JSKN003’s regulatory review and clinical development globally, benefiting cancer patients while enhancing the company’s international credibility.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its Investigational New Drug (IND) application for JSKN027, a first-in-class PD-L1/VEGFR2 bispecific antibody-drug conjugate (ADC), has been officially accepted by China’s Center for Drug Evaluation (CDE). This milestone positions JSKN027 as a potentially groundbreaking treatment for advanced malignant solid tumors, offering a robust three-fold synergistic mechanism that emphasizes targeted chemo, immune checkpoint disruption, and anti-angiogenesis effects. Its acceptance reflects the company’s innovative approach and reinforces its standing in the competitive oncology space, potentially providing significant benefits to patients and stakeholders.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced a decision to repurchase up to HK$30 million worth of its own shares from the open market, as authorized by a mandate approved at their annual general meeting. This move is intended to reflect the company’s confidence in its business prospects and to potentially enhance shareholder value, while being financed through existing cash reserves. The repurchase plan is subject to market conditions and regulatory compliance, with no guarantee on the timing or quantity of shares to be repurchased.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its drug JSKN003 has received Fast Track Designation from the U.S. FDA for treating platinum-resistant recurrent epithelial ovarian cancer and related conditions. This designation highlights the promising clinical data and potential of JSKN003, which has also received multiple designations for other cancers, indicating strong international regulatory confidence. The development of JSKN003 addresses a significant unmet need in ovarian cancer treatment, offering improved efficacy over existing therapies and potentially expediting its clinical development and regulatory review.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its drug JSKN003 has received Fast Track Designation from the U.S. FDA for treating platinum-resistant recurrent epithelial ovarian cancer and related conditions. This designation highlights the promising clinical data and potential of JSKN003, which has also received multiple designations for other cancers, indicating strong international regulatory confidence. The development of JSKN003 addresses a significant unmet need in ovarian cancer treatment, offering improved efficacy over existing therapies and potentially expediting its clinical development and regulatory review.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced the grant of 1,990,176 award shares under its Restricted Share Award Scheme to three eligible participants, including two executive directors and an employee. This move is part of the company’s strategy to reward and incentivize key personnel, aligning with its remuneration policy and long-term growth objectives. The shares will vest in batches over a period of up to ten years, reflecting the company’s commitment to retaining talent and enhancing its competitive positioning in the oncology sector.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced that its drug JSKN003, co-developed with Shanghai JMT-Bio Technology, has been granted breakthrough therapy designation by the CDE for treating HER2+ advanced colorectal cancer (CRC) in patients who have failed prior treatments. This designation highlights the significant unmet clinical need in China, where CRC is highly prevalent, and no HER2-targeted therapies are currently approved. Preliminary results from clinical trials show JSKN003’s notable efficacy and favorable safety profile, potentially positioning it as a promising treatment option for HER2-overexpressing CRC patients.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced promising research updates for its drug JSKN003, presented at the ESMO Congress 2025. The drug showed significant efficacy and a manageable safety profile in treating patients with primary platinum-refractory ovarian cancer (OC) and HER2+ metastatic colorectal cancer (CRC). The results indicate a potential new treatment option for these patient groups, which have limited existing therapies. The company is also progressing with a phase III study comparing JSKN003 to standard chemotherapy in patients with platinum-resistant ovarian cancer (PROC), which could further establish its position in the oncology market.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology announced promising interim results from a Phase III clinical trial of KN026, a next-generation HER2-targeted therapy, in combination with chemotherapy for HER2+ gastric cancer patients. The trial demonstrated significant improvements in progression-free survival and overall survival compared to chemotherapy alone, with a manageable safety profile, positioning KN026 as a potential new treatment option for patients who have progressed on trastuzumab-based therapy.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has released additional information regarding its 2024 Annual Report, focusing on the utilization of treasury shares, proceeds from its Global Offering and Top-up Placing, and its Post-IPO Share Award Scheme. The company has yet to decide on the use of its treasury shares, while significant proceeds remain allocated for the development and commercialization of its key drug candidates KN046 and KN026. Additionally, funds from the Top-up Placing are primarily directed towards clinical trials and development of other drug candidates. The announcement clarifies that the Post-IPO Share Award Scheme does not require further disclosure under the Listing Rules, and the new information does not alter the previously disclosed details in the annual report.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
Alphamab Oncology has announced a voluntary on-market share repurchase plan, with the board resolving to buy back shares worth up to HK$20 million. The decision reflects the company’s confidence in its business prospects and aims to enhance shareholder value, though the execution of the repurchase will depend on market conditions.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.